Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19

J Viral Hepat. 2022 Jul;29(7):579-583. doi: 10.1111/jvh.13686. Epub 2022 May 23.

Elena Vargas-Accarino^{1

2}, Joan Martínez-Campreciós^{1

2}, Raquel Domínguez-Hernández³, Ariadna Rando-Segura^{4

5}, Mar Riveiro-Barciela^{1

2

6}, Francisco Rodríguez-Frías^{6

7

8}, Ana Barreira^{1

2}, Adriana Palom^{1

2}, Miguel Ángel Casado³, Rafael Esteban^{1

6}, María Buti^{1

2

6}

¹ Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
² Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
⁴ Department of Microbiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
⁵ Department of Microbiology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
⁶ CIBERehd, Instituto Carlos III, Barcelona, Spain.
⁷ Biochemistry and Microbiology Department, Clinical Laboratories Hospital Universitari Vall d'Hebron, Barcelona, Spain.
⁸ Liver Pathology Unit, Biochemistry and Microbiology Departments, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

No abstract available

Keywords: COVID-19 pandemic; cost-effectiveness analysis; hepatitis C elimination; linkage to care; lost to follow-up patients.

Publication types